TCGA-A7-A3RF-01A-11R-A22K-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 14
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.420
- ADIPOGENESIS+0.210
- FATTY_ACID_METABOLISM+0.150
- GLYCOLYSIS+0.150
- MYOGENESIS+0.150
- HEME_METABOLISM+0.140
- BILE_ACID_METABOLISM+0.120
- HEDGEHOG_SIGNALING+0.110
- MYC_TARGETS_V2+0.110
- HYPOXIA+0.100
Top 10 suppressed
- E2F_TARGETS-0.490
- ALLOGRAFT_REJECTION-0.460
- IL6_JAK_STAT3_SIGNALING-0.460
- G2M_CHECKPOINT-0.450
- INTERFERON_GAMMA_RESPONSE-0.400
- INFLAMMATORY_RESPONSE-0.380
- NOTCH_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- INTERFERON_ALPHA_RESPONSE-0.310
- TGF_BETA_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1050 | — | — | 0.861 |
| 2 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.845 |
| 3 | SRR1385124 | GTEX | — | 0.832 |
| 4 | TCGA-B6-A0X4-01A-11R-A109-07 | — | B | 0.825 |
| 5 | SRR1437538 | GTEX | — | 0.820 |
| 6 | SRR8518211 | — | C | 0.816 |
| 7 | MDT-AP-2103 | Med | Medulloblastoma | 0.813 |
| 8 | SRR1386708 | GTEX | — | 0.812 |
| 9 | TCGA-OL-A6VR-01A-32R-A33J-07 | — | B | 0.810 |
| 10 | TCGA-GM-A2DC-01A-11R-A18M-07 | — | B | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |